| Dr. David Gratzer |
| Dr. David Gratzer is a Manhattan Institute Center for Medical Progress Senior Fellow, physician, and writer. Gratzer's research interests include Medicare and Medicaid, drug importation, drug price controls and FDA reform. |
Medical Reform
Prescription Drug Policy
Covering the Uninsured |
| Regina E. Herzlinger |
| Regina E. Herzlinger is a Manhattan Institute Center for Medical Progress Senior Fellow. Herzlinger writes on Consumer-Driven Health Care issues. |
Healthcare Industry
Healthcare Insurance |
| Paul Howard |
| Paul Howard is a Senior Fellow and the Director of the Manhattan Institute's Center for Medical Progress. Howard's research interests include FDA reform, Medicare and Medicaid policy initiatives, drug importation, and drug price controls. |
FDA Regulation
Medical Innovation Consumer Driven Health Care |
| Dr. Thomas P. Stossel |
| Dr. Thomas P. Stossel is a Manhattan Institute Center for Medical Progress Senior Fellow. Stossel's research focuses on the role of public and private partnerships in advancing medical innovation. |
Consumer Driven Health Care
Pharmaceutical Industry
Medical Innovation |
|
| For more information on the Center for Medical Progress, please contact Hannah Martone, (212) 599-7000, fax (212) 599-3494. |
| |
|
The Center for Medical Progress is dedicated to articulating the importance of medical progress and the connection between free-market institutions and making medical progress both possible and widely available throughout the world. We encourage the development of market-based policy alternatives to sustain medical progress and promote medical innovation. The Center for Medical Progress also publishes www.MedicalProgressToday.com, a web magazine devoted to chronicling the connections among private sector investment, biomedical innovation, market friendly public policies, and medical progress.
The Center for Medical Progress produces a variety of publications and
hosts regular forums on issues of concern to medical progress and health
care policy. For more information, please contact CMP director Paul Howard
at communications@manhattan-institute.org.
ISSUE
AREAS:
FDA Reform
Articles |
Reports |
Events
Drug Importation/Price Controls
Articles
| Reports
Medicare/Medicaid
Articles |
Events
Consumer Driven Health Care
Articles
| Events
FDA Reform and Medical Innovation
The discovery of rare side effects from drugs like Vioxx and Celebrex has politicians and the media clamoring for larger, longer, and more expensive clinical trials by the Food and Drug Administration. But there is no evidence that reliance on additional "one-size-fits-all" clinical trials will make prescription drugs safer. Moreover, it will cost more lives due to slowed access to new medicines. The CMP's prescription for reform is more science, not more regulation. Science-driven FDA reform can help improve drug safety, streamline drug development and accelerate the adoption of personalized medicine. To achieve these goals, the Manhattan Institute has formed a 21st Century FDA Task Force composed of leading experts that will develop a platform for FDA reform that will help the agency meet health care challenges in the 21st century using cutting-edge science and market-friendly policies.
Select Articles about FDA Reform and Medical Innovation:
- Borrow From The HIV Battle Plan To Help Win War Against Cancer Investor's Business Daily, Tomas Philipson, 03-14-09
- Don't surrender innovation in the name of health care reform Washington Examiner, Tomas Philipson, 03-11-09
- Who Pays for a Cancer Drug?, Peter W. Huber, Forbes, 01-06-09
- Curing Diversity, Peter W. Huber, City Journal, Autumn 2008
- The FDA and drug pre-emption, Tomas Philipson, Chairman, Project FDA, Washington Times, 10-20-08
- Free-Market Medicine, Paul Howard, National Review Online, 08-20-08
• Paul Howard reads Free-Market Medicine
- Conflicted doctors, Peter Huber, Forbes, 04-07-08
- Overwarning, Undercuring, Marie Gryphon, City Journal, 4-04-08
- Leave It to the FDA, Jim Copland, WashingtonPost.com, 03-15-08
- Health care innovation, and its enemies, David Gratzer, Baltimore Examiner, 02-07-08
- Where Are the Innovators in Health Care?, Regina Herzlinger, Harvard Business Alumni Bulletin, December 2007
- How The New Medicine Renders Universal Health Care Impossible, Peter Huber, Investor's Business Daily, 10-29-07
- On Vaccines, Immune to Reason, Paul Howard, WashingtonPost.com, 10-12-07
- Should the federal government negotiate directly with pharmaceutical companies?, Benjamin Zycher, Medicare Patient Management, July/August 2007
- Where Are the Innovators in Health Care?, Regina Herzlinger, Wall Street Journal, 7-19-07
- A Story Michael Moore Didn't Tell, Paul Howard, WashingtonPost.com, 07-17-07
- FDA User Fees Is Rx To Speed Drug Approvals, David Gratzer, Investor's Business Daily, 07-06-07
- Pharmaceutical litigation for all, and safety for none, Paul Howard, Washington Examiner, 06-19-07
- Fear is Side Effect of Drug Warnings, Paul Howard, RealClearPolitics, 06-04-07
- FDA Must Test Some Biologics' Generic Forms, Paul Howard, Investor's Business Daily, 04-12-07
- Getting a Handle on Public Health, Paul Howard, The American, 02-16-07
- What policymakers can learn from a $21 billion failure, Paul Howard, Washington Examiner, 01-03-07
Select Reports about FDA Reform and Medical Innovation:
Select Events about FDA Reform and Medical Innovation:
- "The FDA and PDFUA: Timely Review or Unsafe Approval?",
June 23, 2008, Capitol Hill, Washington, DC
Speakers: Tomas Philipson, University of Chicago, and Theresa Mullin, Food and Drug Administration
Moderator: Paul Howard, Manhattan Institute's Center for Medical Progress
- New York's Uninsured: Looking Back and Moving Forward,
December 11, 2007, New York City
Panel One: New York's Uninsured: A History of Good Intentions and Unintended Consequences
James R. Tallon, Jr., President, United Hospital Fund of New York, Mark Scherzer, Legislative Counsel, New Yorkers for Accessible Health Coverage, Tarren Bragdon, Health Policy Analyst, Empire Center for New York State Policy
Moderator: Howard Husock, Vice President, Policy Research, Manhattan Institute
Panel Two: Public Sector Experiments: Mandates, Medicaid, and Markets
Nina Owcharenko, Senior Policy Analyst, Center for Health Policy Studies, Heritage Foundation, Jon Kingsdale, Ph.D., Executive Director, Commonwealth Health Insurance Connector Authority, Len Nichols, Ph.D., Director, Health Policy Program, New America Foundation, David Gratzer, Senior Fellow, Manhattan Institute's Center for Medical Progress
Moderator: Paul Howard, Director, Manhattan Institute's Center for Medical Progress
Keynote Address: Charles D. Baker, Chief Executive Officer, Harvard Pilgrim Health Care
Drug Importation/Price Controls
The U.S. is the world's leader in biopharmaceutical innovation, mainly because the U.S. does not impose price controls on prescription drugs. However, the rise of the internet has given individual U.S. consumers access to drugs in price controlled countries, leading to a growing demand that policymakers legalize importation on a national level. This policy would undermine medical innovation, while sending pharmaceutical investment and innovation now conducted in the U.S. to our rapidly developing competitors in China and India. The CMP is devoted to cataloguing the benefits of market driven medical innovation, both in economic and human terms, and in shifting the debate on drug importation to a question of free trade. After all, since the entire world benefits from the premium U.S. consumers pay for drug research and development, U.S. trade negotiators should encourage rich nations to help bear the full costs of drug development.
Select Articles about Drug Importation/Price Controls:
- Drug Imports: The Unappreciated Downside, Benjamin Zycher, Investor's Business Daily, 05-08-07
- McCain is wrong on drugs, David Gratzer, Washington Examiner, 03-20-08
- Thai-ing Up Innovation, Paul Howard, National Review Online, 03-20-07
- License to Ill, Benjamin Zycher, National Review Online, 01-11-07
- Canada's prescription drug supply in danger? Take a pill, David Gratzer, Globe and Mail, 01-07-07
Select Reports about Drug Importation/Price Controls:
Medicare/Medicaid
Medicare and Medicaid are the nation's two largest entitlement programs. They are also facing multi-trillion dollar deficits in coming decades as expenditures dwarf tax revenues. While some have advocated that the U.S. adopt a Canadian-style "single-payer" health care system to reign in costs, the Manhattan Institute recognizes that price controls and rationing will only exacerbate the health care challenges facing our nation, not solve them. Reforming these programs means opening Medicare and Medicaid to private insurance markets and putting consumers, not bureaucrats, in control of their own health care spending through health savings accounts and targeted vouchers. Empowered consumers make rational, cost-effective choices without dampening the market incentives driving health care innovation.
Select Articles about Medicare/Medicaid:
- Medical Drama, Paul Howard, New York Post, 05-11-08
- Democrats' Health Plan Not So Harmless, Benjamin Zycher, Investor's Business Daily, 02-15-08
- Time to Rechristen SCHIP, David Gratzer, City Journal Online, 8 February 2008
- The free lunch never dies, Benjamin Zycher, The Hill, 11-14-07
- Free Lunch Eternal, Benjamin Zycher, National Review Online, 10-18-07
- False Accounting And Free Lunches Under A Single-Payer Health System, Benjamin Zycher, Investor's Business Daily, 10-17-07
- Congress is Full of SCHIP, Paul Howard, National Review Online, 07-31-07
Select Reports about Medicare/Medicaid:
Select Events about Medicare/Medicaid:
- Comparing Public and Private Health Insurance: Would a Single-Payer System Save Enough to Cover the Uninsured?, October 17, 2007, New York City
Speaker: Benjamin Zycher, Senior Fellow, Manhattan Institute for Policy Research
Discussant: June O'Neill, Wollman Distinguished Professor of Economics and Finance, Baruch College, Director, Congressional Budget Office (1995-1999)
Moderator: Howard Husock, Vice President of Programs, Manhattan Institute for Policy Research
Consumer Driven Health Care
Third-party payment plans allow some consumers to use services without ever paying the full cost of health care utilization, while others pay for benefits they don't need. The result is a system where health care costs spiral out of control and consumer choice is limited to "one-size-fits-all" medicine. The CMP wants to change this system by making it a true market: putting consumers in charge of their own routine health care spending; reserving insurance for truly catastrophic injuries; and creating a national market for health insurance that encourages customized insurance plans and pricing competition.
Select Articles about Consumer Driven Health Care:
- Data shows health savings accounts cut premiums, Benjamin Zycher, Washington Examiner, 02-18-09
- The case for the McCain health care plan, David Gratzer and Paul Howard, Dallas Morning News, 05-19-08
- Memo to McCain: Talk About Health Care, David Gratzer, Arizona Republic, 04-07-08
- Both Parties Prescribe Bad Medicine In The Form Of Insurance Mandates, David Gratzer and Paul Howard, Investor's Business Daily, 03-31-08
- Mandates Are Not the Answer, David Gratzer, City Journal Online, 31 March 2008
- America, Insure Thyself, Regina Herzlinger, WashingtonPost.com, 03-29-08
- The holes in universal health care plan, David Gratzer, Newark Star-Ledger, 03-25-08
- Running for the Exits, Regina Herzlinger, National Review Online, 02-22-08
- Dust Off Last Year's Health Reform For This Year's State Of The Union, David Gratzer, Investor's Business Daily, 01-28-08
- Foreign Health Affairs, Regina Herzlinger, Wall Street Journal, 11-19-07
Select Reports about Consumer Driven Health Care:
Select Events on Consumer Driven Health Care:
- Reforming Our Health Care System, November 1, 2007, New York City
Speakers: Richard A. Epstein, J.D. Visiting Scholar, Manhattan Institute's Center for Legal Policy James Parker Hall Distinguished Service Professor of Law, University of Chicago Peter and Kirstin Bedford Senior Fellow, Hoover Institution,
Theodore R. Marmor, Ph.D. Professor Emeritus of Public Policy and Management, Yale School of Management Adjunct Professor Emeritus, Yale Law School
- Who Killed Health Care? America's $2 Trillion Problemand the Consumer-Driven Cure, June 5, 2007, New York City
Speaker: Regina E. Herzlinger, Senior Fellow, Manhattan Institute
- Health Care: Does the Free Market Apply?, February 15, 2007, New York City
Participants: Dr. David Gratzer, Senior fellow at the Manhattan Institute Center for Medical Progress, Daniel Callahan, Senior fellow at the Hastings Center
Moderator: Brian Lehrer, Host of WNYC's "The Brian Lehrer Show"
(Click here for video)
|
| NEW
REPORT |
Forging a New Plan For Healthcare: Principles and Priorities for Sustainable Reform
By Douglas Holtz-Eakin May 18, 2009
Click here to read the entire report.
PODCAST:
Paul Howard, director of the Center for Medical Progress, interviews Douglas Holtz-Eakin about his new report.
Click here to listen to the podcast.
OP-ED:
Betting
the future on it, Douglas Holtz-Eakin, Washington Times, 6-17-09
IN THE PRESS:
GOP
Explores Ways to Repitch the ‘Big Tent’, Congressional Quarterly, 5-23-09
The Republicans Weigh In with
a Health-Care Plan, Time Magazine, 5-21-09
More Value, Private Coverage Essential To Health
Reform, Former CBO Head Says, Bureau of National Affairs, 5-19-09 (subscription required)
Holtz-Eakin calls for focus on private insurance market, Smart Brief, 5-19-09
What
is the formula for sustainable healthcare reform? News Medical, 5-19-09
Senate Finance
Outlines Options for Paying for Health Reform, Roll Call, 5-18-09 (subscription required)
Former CBO Director Proposes Reform Plan, Washington Post, 5-18-09
Ex-CBO Chief Pushes Access
Via Private Insurance, Modern Healthcare, 5-18-09 (free subscription required)
|
TESTIMONY:
On Wednesday, June 24, 2009, David Gratzer, senior fellow at the Center for Medical Progress, appeared before the Ways and Means Committee
to testify about his experiences with the Canadian single-payer healthcare system.
Click here to read his statement. |

|